{"id":"https://openalex.org/W2889854070","doi":"https://doi.org/10.1007/s11136-018-1984-3","title":"Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis","display_name":"Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis","publication_year":2018,"publication_date":"2018-09-06","ids":{"openalex":"https://openalex.org/W2889854070","doi":"https://doi.org/10.1007/s11136-018-1984-3","mag":"2889854070","pmid":"https://pubmed.ncbi.nlm.nih.gov/30191365"},"language":"en","primary_location":{"id":"doi:10.1007/s11136-018-1984-3","doi":"https://doi.org/10.1007/s11136-018-1984-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s11136-018-1984-3","pdf_url":null,"source":{"id":"https://openalex.org/S90347677","display_name":"Quality of Life Research","issn_l":"0962-9343","issn":["0962-9343","1573-2649"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","fnege-3","jufo-3","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Quality of Life Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210134579","display_name":"Dana-Farber/Harvard Cancer Center","ror":"https://ror.org/03pvyf116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I136199984","https://openalex.org/I4210117453","https://openalex.org/I4210134579"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David F. McDermott","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA. dmcdermo@bidmc.harvard.edu","Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA. dmcdermo@bidmc.harvard.edu","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984","https://openalex.org/I4210134579"]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I4210134579"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063504590","display_name":"Ruchit Shah","orcid":"https://orcid.org/0000-0002-3553-6142","observed_orcids":["https://orcid.org/0000-0002-3553-6142"]},"institutions":[{"id":"https://openalex.org/I4210134090","display_name":"Pharmerit (United States)","ror":"https://ror.org/040d4nb67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210134090"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruchit Shah","raw_affiliation_strings":["Pharmerit International, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit International, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210134090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042065087","display_name":"Komal Gupte-Singh","orcid":"https://orcid.org/0000-0002-4886-6183","observed_orcids":["https://orcid.org/0000-0002-4886-6183","https://orcid.org/0000-0003-2010-3595"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Komal Gupte-Singh","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005075669","display_name":"Javier Sabater","orcid":"https://orcid.org/0000-0001-7970-6679","observed_orcids":["https://orcid.org/0000-0001-7970-6679"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4210135308","display_name":"Servier (France)","ror":"https://ror.org/034e7c066","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210135308"]}],"countries":["FR","US"],"is_corresponding":false,"raw_author_name":"Javier Sabater","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA","Servier, Suresnes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Servier, Suresnes, France","institution_ids":["https://openalex.org/I4210135308"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042331907","display_name":"Linlin Luo","orcid":"https://orcid.org/0009-0005-0920-4901","observed_orcids":["https://orcid.org/0009-0005-0920-4901","https://orcid.org/0000-0002-0672-4267"]},"institutions":[{"id":"https://openalex.org/I4210134090","display_name":"Pharmerit (United States)","ror":"https://ror.org/040d4nb67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210134090"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linlin Luo","raw_affiliation_strings":["Pharmerit International, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit International, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210134090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087184017","display_name":"Marc F Botteman","orcid":"https://orcid.org/0000-0003-2808-7163","observed_orcids":["https://orcid.org/0000-0003-2808-7163"]},"institutions":[{"id":"https://openalex.org/I4210134090","display_name":"Pharmerit (United States)","ror":"https://ror.org/040d4nb67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210134090"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc Botteman","raw_affiliation_strings":["Pharmerit International, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit International, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210134090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109110234","display_name":"Sumati A. Rao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sumati Rao","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017334876","display_name":"Meredith M. Regan","orcid":"https://orcid.org/0000-0002-2428-6109","observed_orcids":["https://orcid.org/0000-0002-2428-6109"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meredith M. Regan","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052526230","display_name":"Michael B. Atkins","orcid":"https://orcid.org/0000-0003-3901-9924","observed_orcids":["https://orcid.org/0000-0003-3901-9924"]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]},{"id":"https://openalex.org/I4390039356","display_name":"Georgetown Lombardi Comprehensive Cancer Center","ror":"https://ror.org/035zrb927","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184565670","https://openalex.org/I4390039356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Atkins","raw_affiliation_strings":["Lombardi Cancer Center, Georgetown University, Washington, DC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lombardi Cancer Center, Georgetown University, Washington, DC, USA","institution_ids":["https://openalex.org/I184565670","https://openalex.org/I4390039356"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5007052233"],"corresponding_institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984","https://openalex.org/I4210134579"],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":1.0564,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.79857012,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"28","issue":"1","first_page":"109","last_page":"119"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6675000190734863,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.6675000190734863,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.29249998927116394,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.03020000085234642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.8489999771118164},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7940000295639038},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9800000190734863},{"id":"https://openalex.org/keywords/quality-adjusted-survival","display_name":"quality-adjusted survival","score":0.921999990940094},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.7620000243186951},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.546999990940094},{"id":"https://openalex.org/keywords/checkmate-067","display_name":"CheckMate 067","score":0.7419999837875366},{"id":"https://openalex.org/keywords/health-utility","display_name":"health utility","score":0.5709999799728394},{"id":"https://openalex.org/keywords/eq-5d-3l","display_name":"EQ-5D-3L","score":0.9200000166893005},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7099999785423279},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5080000162124634},{"id":"https://openalex.org/keywords/relapse-free-survival","display_name":"relapse-free survival","score":0.6679999828338623},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.42100000381469727}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9813870787620544},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9577375650405884},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7938752770423889},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5983536839485168},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4514077603816986},{"id":"https://openalex.org/C2776196297","wikidata":"https://www.wikidata.org/wiki/Q17138781","display_name":"Twist","level":2,"score":0.43518128991127014},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3953092694282532},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.30704444646835327},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.13465341925621033},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.049304842948913574},{"id":"https://openalex.org/C2524010","wikidata":"https://www.wikidata.org/wiki/Q8087","display_name":"Geometry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":true},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s11136-018-1984-3","doi":"https://doi.org/10.1007/s11136-018-1984-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s11136-018-1984-3","pdf_url":null,"source":{"id":"https://openalex.org/S90347677","display_name":"Quality of Life Research","issn_l":"0962-9343","issn":["0962-9343","1573-2649"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","fnege-3","jufo-3","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Quality of Life Research","raw_type":"journal-article"},{"id":"pmid:30191365","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30191365","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320324142","display_name":"European Society for Medical Oncology","ror":"https://ror.org/03xtz2n86"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1899661357","https://openalex.org/W1994361201","https://openalex.org/W2008527311","https://openalex.org/W2027743201","https://openalex.org/W2033521428","https://openalex.org/W2054198594","https://openalex.org/W2062624454","https://openalex.org/W2070192320","https://openalex.org/W2088915131","https://openalex.org/W2096782143","https://openalex.org/W2097995306","https://openalex.org/W2100158834","https://openalex.org/W2123363005","https://openalex.org/W2128035403","https://openalex.org/W2128229739","https://openalex.org/W2132757216","https://openalex.org/W2134119471","https://openalex.org/W2136919572","https://openalex.org/W2166662937","https://openalex.org/W2179977652","https://openalex.org/W2199766786","https://openalex.org/W2254058470","https://openalex.org/W2259708582","https://openalex.org/W2263759961","https://openalex.org/W2265847092","https://openalex.org/W2470583568","https://openalex.org/W2516503482","https://openalex.org/W2570618306","https://openalex.org/W2592144107","https://openalex.org/W2636042323","https://openalex.org/W2736166064","https://openalex.org/W2747107882","https://openalex.org/W2753432434","https://openalex.org/W2765752537","https://openalex.org/W2770122187","https://openalex.org/W2792113799","https://openalex.org/W2807907317","https://openalex.org/W6633658626"],"related_works":["https://openalex.org/W2763717235","https://openalex.org/W2513648362","https://openalex.org/W3043703771","https://openalex.org/W4408855355","https://openalex.org/W2027743201","https://openalex.org/W2244967365","https://openalex.org/W2613014804","https://openalex.org/W2741245320","https://openalex.org/W2978880457","https://openalex.org/W4282022545"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-09-27T00:00:00"}